最新消息
News
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress漢康生技於第11屆亞太胃食管癌大會發表 HCB101 三藥聯合療法於二線胃癌之具劑量依賴性的腫瘤反應與持續腫瘤縮小數據
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical data from its ongoing HCB101-201 Phase 1b/2a study at the 11th Asia-Pacific Gastroesophageal Cancer Congress (APGCC). The poster highlights early findings supporting dose-dependent antitumor activity of HCB101 in combination with ramucirumab and paclitaxel among patients with advanced gastric adenocarcinoma who progressed after first-line therapy.
3 月 05, 2026
Read more
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026漢康生技於美國癌症研究協會 (AACR) 腫瘤免疫學年會發表 HCB101 單藥與聯合治療的臨床數據
HanchorBio Presents Monotherapy and Combination Clinica […]
2 月 19, 2026
Read more
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer漢康廣譜抗癌新藥HCB101獲孤兒藥認定 推進晚期胃癌新療法
HanchorBio Receives FDA Orphan Drug Designation for HCB […]
2 月 13, 2026
Read more
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101漢康生技創新 SIRPα/CD47 融合蛋白生物藥 HCB101 獲日本專利核准
HanchorBio Secures Japanese Patent for Engineered SIRPα […]
1 月 23, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation漢康生技於2026 ASCO GI消化道腫瘤大會發表 HCB101 聯合標準治療在二線胃癌之臨床數據
HanchorBio Reports High Objective Response Rate with HC […]
1 月 09, 2026
Read more
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more